A systematic approach to diabetic foot infections

Advances in Therapy

Volumn 22, Issue 3, 2005, Pages 244-262

  Zgonis, Thomas ^a   Roukis, Thomas S ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b WEIL FOOT AND ANKLE INSTITUTE   (United States)

Author keywords

Antibiotic therapy; Diabetic foot infections; Surgery

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAMASE INHIBITOR; CEFADROXIL; CEFALEXIN; CEFAZOLIN; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DICLOXACILLIN; ERTAPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; NAFCILLIN; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC THERAPY; BLOOD CULTURE; BONE INFECTION; DEBRIDEMENT; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC NEUROPATHY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; FOOT ULCER; HOSPITALIZATION; HUMAN; HYPERBARISM; INJURY; LEG AMPUTATION; OSTEOMYELITIS; PERIPHERAL VASCULAR DISEASE; REVIEW; SIDE EFFECT; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; STREPTOCOCCUS; SURGICAL DRAINAGE; VASCULAR SURGERY; WOUND HEALING; WOUND INFECTION;

EID: 25444475821     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02849934     Document Type: Review

References (141)

1. Lipsky BA. Medical treatment of diabetic foot infections. Clin Infect Dis. 2004;39:S104-S114.
2. Armstrong DG, Lipsky BA. Advances in the treatment of diabetic foot infections. Diabetes Technol Ther. 2004;6:167-177.
3. Lipsky BA, Berendt AR. Principles and practice of antibiotic therapy of diabetic foot infections. Diabetes Metab Res Rev. 2000;16:S42-S46.
4. Tan JS, Friedman NM, Hazelton-Miller C, Flanagan JP, File TM. Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation? Clin Infect Dis. 1996;23: 286-291.
5. Zgonis T, Jolly GP, Buren BJ, Blume P. Diabetic foot infections and antibiotic therapy. Clin Podiatr Med Surg. 2003;20:655-669.
6. Lipsky BA, Berendt AR, Embil J, De Lalla F. Diagnosing and treating diabetic foot infections. Diabetes Metab Res Rev. 2004;20:S56-S64.
7. Kaleta JL, Fleischli JW, Reilly CH. The diagnosis of osteomyelitis in diabetes using the erythrocyte sedimentation rate: a pilot study. J Am Podiatric Med Assoc. 2001;91:445-450.
8. Pellizzer G, Strazzabosco M, Presi S, et al. Deep tissue biopsy vs. superficial swab culture monitoring in the microbiological assessment of limb-threatening diabetic foot infection. Diabet Med. 2001;18:822-827.
9. Grayson ML, Gibbons GW, Balogh K, Levin E, Karcmer AW. Probing to bone in infected pedal ulcers: A clinical sign of underlying osteomyelitis in diabetic patients. JAMA. 1995;273:721-723.
10. Howard CB, Einhorn M, Dagan R, Yagupski P, Porat S. Fine-needle bone biopsy to diagnose osteomyelitis. J Bone Joint Surg Br. 1994;76:311-314.
11. Caprioli R, Testa J, Cournoyer RW Jr, Esposito FJ. Prompt diagnosis of suspected osteomyelitis by utilizing percutaneous bone culture. J Foot Surg. 1986;25:263-269.
12. Khatri G, Wagner DK, Sohnle PG. Effect of bone biopsy in guiding antimicrobial therapy for osteomyelitis complicating open wounds. Am J Med Sci. 2001;321:367-371.
13. Zuluaga AF, Galvis W, Jaimes F, Vesga O. Lack of microbiological concordance between bone and non-bone specimens in chronic osteomyelitis: an observational study. BMC Infect Dis. 2002;2:8.
14. Newman LG. Imaging techniques in the diabetic foot. Clin Podiatr Med Surg. 1995;12:75-86.
15. Harvey J, Cohen MM. Technetium-99 labeled leukocytes in diagnosing diabetic osteomyelitis in the foot. J Foot Ankle Surg. 1997;36:209-214.
16. Marcus CD, Ladam-Marcus VJ, Leone J, Malgrange D, Bonnet-Gausserand FM, Menanteau BP. MR imaging of osteomyelitis and neuropathic osteoarthropathy in the feet of diabetics. Radiographics. 1996;16:1337-1348.
17. Craig JG, Amin MB, Wu K, et al. Osteomyelitis of the diabetic foot: MR imaging-pathologic correlation. Radiology. 1997;203:849-855.
18. Sella EJ, Grosser DM. Imaging modalities of the diabetic foot. Clin Podiatr Med Surg. 2003;20: 729-740.
19. Lipman BT, Collier BD, Carrera GF, et al. Detection of osteomyelitis in the neuropathic foot: nuclear medicine, MRI and conventional radiography. Clin Nucl Med. 1998;23:77-82.
20. Bonakdarpour A, Gaines VD. The radiology of osteomyelitis. Orthop Clin North Am. 1983; 14:21.
21. Tomas MB, Patel M, Marwin SE, Palestro CJ. The diabetic foot. Br J Radiol. 2000;73:443-450.
22. Gold RH, Tong DJ, Crim JR, Seeger LL. Imaging the diabetic foot. Skeletal Radiol. 1995;24:563-571.
23. Poirier JY, Garin E, Derrien C, et al. Diagnosis of osteomyelitis in the diabetic foot with a 99mTc-HMPAO leucocyte scintigraphy combined with a 99mTc-MDP bone scintigraphy. Diabetes Metab. 2002;28:485-490.
24. Devillers A, Moisan A, Hennion F, Garin E, Poirier JY, Bourguet P. Contribution of technetium-99m hexamethylpropylene amine oxime labelled leucocyte scintigraphy to the diagnosis of diabetic foot infection. Eur J Nucl Med. 1998;25:132-138.
25. Harvey J, Cohen MM. Technetium-99-labeled leukocytes in diagnosing diabetic osteomyelitis in the foot. J Foot Ankle Surg. 1997;36:209-214.
26. Boc SF, Brazzo K, Lavian D, Landino T. Acute Charcot foot changes versus osteomyelitis: does Tc-99m HMPAO labeled leukocytes scan differentiate? J Am Podiatr Med Assoc. 2001;91:365-368.
27. Sarikaya A, Aygit AC, Pekindil G. Utility of 99mTc dextran scintigraphy in diabetic patients with suspected osteomyelitis of the foot. Ann Nucl Med. 2003;17:669-676.
28. Schauwecker DS, Park HM, Burt RW, Mock BH, Wellman HN. Combined bone scintigraphy and indium-111 leukocyte scans in neuropathic foot disease. J Nucl Med. 1988;29:1651-1655.
29. Johnson JE, Kennedy EJ, Shereff MJ, Patel NC, Collier BD. Prospective study of bone, indium-111-labeled white blood cell, and gallium-67 scanning for the evaluation of osteomyelitis in the diabetic foot. Foot Ankle Int. 1996;17:10-16.
30. Becker W. Imaging osteomyelitis and the diabetic foot. Q J Nucl Med. 1999;43:9-20.
31. Palestro CJ, Mehta HH, Patel M. Marrow versus infection in the Charcot joint: indium-111 leukocyte and technetium-99m sulfur colloid scintigraphy. J Nucl Med. 1998;39:346-350.
32. Palestro CJ, Caprioli R, Love C, et al. Rapid diagnosis of pedal osteomyelitis in diabetics with a technetium-99m-labeled monoclonal antigranulocyte antibody. J Foot Ankle Surg. 2003;42:2-8.
33. Devillers A, Garin E, Polard JL, et al. Comparison of Tc-99m-labelled antileukocyte fragment Fab′ and Tc-99m-HMPAO leukocyte scintigraphy in the diagnosis of bone and joint infections: a prospective study. Nucl Med Commun. 2000;2:747-753.
34. Palestro CJ, Kipper SL, Weiland FL, Love C, Tomas MB. Osteomyelitis: diagnosis with (99m) Tc-labeled antigranulocyte antibodies compared with diagnosis with (111) In-labeled leukocytes-initial experience. Radiology. 2002;223:758-764.
35. Von Rothenburg T, Schaffstein J, Ludwig J, Vehling D, Koster O, Schmid G. Imaging osteomyelitis with Tc-99m-labeled antigranulocyte antibody Fab′ fragments. Clin Nucl Med. 2003;28:643-647.
36. Harwood SJ, Valdivia S, Hung GL, Quenzer RW. Use of Sulesomab, a radiolabeled antibody fragment, to detect osteomyelitis in diabetic patients with foot ulcers by leukoscintigraphy. Clin Infect Dis. 1999;28:1200-1205.
37. Morrison WB, Schweitzer ME, Wapner KL, Hecht PJ, Cannon FH, Behm WR. Osteomyelitis in feet of diabetics: clinical accuracy, surgical utility, and cost-effectiveness of MR imaging. Radiology. 1995;196:557-564.
38. Croll SD, Nicholas GG, Osborne MA, Wasser TE, Jones S. Role of magnetic resonance imaging in the diagnosis of osteomyelitis in diabetic foot infections. J Vasc Surg. 1996;24:266-270.
39. Weinstein D, Wang A, Chambers R, Stewart CA, Motz HA. Evaluation of magnetic resonance imaging in the diagnosis of osteomyelitis in diabetic foot infections. Foot Ankle. 1993;14:18-22.
40. Cook TA, Rahim N, Sompson HCR, Gelland RB. Magnetic resonance imaging in the management of diabetic foot infection. Br J Surg. 1996;83:245-248.
41. Ledermann HP, Morrision WB, Schweitzer ME, Raikin SM. Tendon involvement in pedal infection: MR analysis of frequency, distribution, and spread of infection. Am J Roent. 2002; 179:939-947.
42. Gold RH, Hawkins RA, Katz RD. Bacterial osteomyelitis: findings on plain radiography, CT, MR, and scintigraphy. AJR Am J Roentgenol 1991;157:365-370.
43. Tehranzadeh J, Wong E, Wang F, Sadighpour M. Imaging of osteomyelitis in the mature skeleton. Radiol Clin North Am. 2001;39:223-250.
44. Enderle MD, Coerper S, Schweizer HP, et al. Correlation of imaging techniques to histopathology in patients with diabetic foot syndrome and clinical suspicion of chronic osteomyelitis. The role of high-resolution ultrasound. Diabetes Care. 1999;22:294-299.
45. Sammak B, Abd El Bagi M, Al Shahed M. Osteomyelitis: a review of currently used imaging techniques. Eur Radiol. 1999;9:894-900.
46. Wrobel JS, Connolly JE. Making the diagnosis of osteomyelitis. The role of prevalence. J Am Podiatr Med Assoc. 1998;88:337-343.
47. O'Meara SM, Cullum NA, Majid M, Sheldon TA. Systemic review of antimicrobial agents used for chronic wounds. Br J Surg. 2001;88:4-21.
48. Lipsky BA. Evidence-based antibiotic therapy of diabetic foot infections. Immunolgy Med Microb. 1999;26:267-276.
49. O'Meara S, Cullum N, Majid M, Sheldon T. Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration. Health Technol Assess. 2000;4:1-237.
50. Bradley M, Cullum N, Nelson EA, Petticrew M, Sheldon T, Torgerson D. Systematic reviews of wound care management: (2). Dressings and topical agents used in the healing of chronic wounds. Health Technol Assess. 1999;3:1-35.
51. Armstrong DG, Findlow AH, Oyibo SO, Boulton AJM. The use of absorbable antibiotic-impregnated calcium sulphate pellets in the management of diabetic foot infections. Diabet Med. 2001;11:942-943.
52. Roeder B, Van Gils CC, Maling S. Antibiotic beads in the treatment of diabetic pedal osteomyelitis. J Foot Ankle Surg. 2000;39:124-130.
53. Scott DM, Rotschafer JC, Behrens F. Use of vancomycin and tobramycin polymethylmethacrylate impregnated beads in the management of chronic osteomyelitis. Drug Intell Clin Pharm. 1988; 22:480-483.
54. Dorigo B, Cameli AM, Trapani M, Raspanti D, Torri M, Mosconi G. Efficacy of femoral intra-arterial administration of teicoplanin in gram-positive diabetic foot infections. Angiology. 1995;46:1115-1122.
55. Lange E. Current surgery/drug combination treatment of diabetic gangrene of the foot. Infection. 1991;19:S351-S354.
56. Connolly JE, Wrobel JS, Anderson RF. Primary closure of infected diabetic foot wounds. A report of closed instillation in 30 cases. J Am Podiatr Med Assoc. 2000;90:175-182.
57. Schmidt J, Hackenbroch MH, Kumm D, Taravati V. Is instillation drainage for the treatment of infected joints, bones and soft tissues still up to date? Arch Orthop Trauma Surg. 1996;115:149-152.
58. Lipsky BA, Pecoraro RE, Larson SA, Hanley ME, Ahroni JH. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch Intern Med. 1990;150:790-797.
59. Frykberg RG, Armstrong DG, Giurini J, et al. Diabetic foot disorders: a clinical practice guideline. J Foot Ankle Surg. 2000;39:S1-S60.
60. Gooch WM III, Kaminester L, Cole GW, et al. Clinical comparison of cefuroxime axetil, cephalexin and cefadroxil in the treatment of patients with primary infections of the skin or skin structures. Dermatologica. 1991;183:36-43.
61. Jennings MB, McCarty JM, Scheffler NM, Puopolo AD, Rothermel CD. Comparison of azithromycin and cefadroxil for the treatment of uncomplicated skin and skin structure infections. Cutis. 2003; 72:240-244.
62. Lipsky BA, Baker PD, Landon GC, Fernau R. Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. Clin Infect Dis. 1997;24:643-648.
63. Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis. 2002;35:381-389.
64. Diamantopoulos EJ, Haritos D, Yfandi G, et al. Management and outcome of severe diabetic foot infections. Exp Clin Endocrinol Diabetes. 1998;106:346-352.
65. Sesin GP, Paszko A, O'Keefe E. Oral clindamycin and ciprofloxacin therapy for diabetic foot infections. Pharmacotherapy. 1990;10:154-156.
66. Nix DE, Cumbo TJ, Kuritzsky P, Devito JM, Schentag JJ. Oral ciprofloxacin in the treatment of serious soft tissue and bone infection in the treatment of serious soft tissue and bone infection: Efficacy, safety and pharmokinetics. Am J Med. 1987;82:146-153.
67. Oberdorfer K, Swoboda S, Hamann A, et al. Tissue and serum levofloxacin concentrations in diabetic foot infection patients. J Antimicrob Chemother. 2004;54:836-983.
68. Peterson LR, Lissack LM, Canter K, Fasching CE, Clabots C, Gerding DN. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. Am J Med. 1989;86:801-808.
69. Greenberg RN, Tice AD, Marsh PK, et al. Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis. Am J Med. 1987;82:266-269.
70. Perez-Ruvalcaba JA, Quintero-Perez NP, Morales-Reyes JJ, Huitron-Ramirez JA, Rodriguez-Chagollan JJ, Rodriguez-Noriega E. Double-blind comparison of ciprofloxacin with cefotaxime in the treatment of skin and skin structure infections. Am J Med. 1987;82:242-246.
71. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997; 32:101-119.
72. Gerding DN. Foot infections in diabetic patients: the role of anaerobes. Clin Infect Dis. 1995; 20:5283-5288.
73. Lipsky BA. Osteomyelitis of the foot in diabetic patients. Clin Infect Dis. 1997;25:1318-1326.
74. Akova M, Ozcebe O, Gullu I, et al. Efficacy of sulbactam-ampicillin for the treatment of severe diabetic foot infections. J Chemother. 1996;8:284-289.
75. Siami G, Christou N, Eiseman I, Tack KJ. Severe Skin and Soft Tissue Infections Study Group. Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrob Agents Chemother. 2001;45:525-531.
76. Zeillemaker AM, Veldkamp KE, van Kraaij MG, Hoekstra JB, Hoynck van Papendrecht AA, Diepersloot RJ. Piperacillin/tazobactam therapy for diabetic foot infection. Foot Ankle Int. 1998;19:169-172.
77. Gorbach SL. Piperacillin/tazobactam in the treatment of polymicrobial infections. Intensive Care Med. 1994;20:S27-S34.
78. File TM Jr, Tan JS. Ticarcillin-clavulanate therapy for bacterial skin and soft tissue infections. Rev Infect Dis. 1991;13:S733-S736.
79. Chan JC. Ampicillin/sulbactam versus cefazolin or cefoxitin in the treatment of skin and skin-structure infections of bacterial etiology. Adv Ther. 1995;12:139-146.
80. Hughes CE, Johnson CC, Bamberger DM, et al. Treatment and long-term follow-up of foot infections in patients with diabetes or ischemia: a randomized, prospective, double-blind comparison of cefoxitin and ceftizoxime. Clin Ther. 1987;10:36-49.
81. File TM Jr, Tan JS. Amdinocillin plus cefoxitin versus cefoxitin alone in therapy of mixed soft tissue infections (including diabetic foot infections). Am J Med. 1983;75:100-105.
82. Jauregui L, Matzke D, Scott M, Minns P, Hageage G. Cefepime as treatment for osteomyelitis and other severe bacterial infections. J Antimicrob Chemother. 1993;32:141-149.
83. Wong BB, Ko GJ. Neutropenia in patients receiving long-term cefepime therapy for osteomyelitis. Am J Health Syst Pharm. 2003;60:2229-2232.
84. Lobmann R, Ambrosch A, Seewald M, et al. Antibiotic therapy for diabetic foot infections: comparison of cephalosporins with chinolones. Diabetes Nutr Metab. 2004;17:156-162.
85. Raymakers JT, Houben AJ, Heyden JJ, Tordoir JH, Kitslaar PJ, Schaper NC. The effect of diabetes and severe ischaemia on the penetration of ceftazidime into tissue of the limb. Diabet Med. 2001; 18:229-234.
86. Raymakers JT, Schaper NC, van der Heyden JJ, Tordoir JH, Kitslaar PJ. Penetration of ceftazidime into bone from severely ischaemic limbs. J Antimicrob Chemother. 1998;42:543-545.
87. Zimmerman J, Silver J, Shapiro M, Friedman G, Melmed RN. Clindamycin unresponsive anaerobic osteomyelitis treated with oral metronidazole. Scand J Infect Dis. 1980;12:79-80.
88. Semel JD, Allen N. Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole. South Med J. 1991;84:465-468.
89. Cooke CE, Sklar GE, Nappi JM. Possible pharmacokinetic interaction with quinidine: ciprofloxacin or metronidazole? Ann Pharmacother. 1996;30:364-366.
90. Cina SJ, Russell RA, Conradi SE. Sudden death due to metronidazole/ ethanol interaction. Am J Forensic Med Pathol. 1996;17:343-346.
91. Grayson ML, Gibbons GW, Habershaw GM, et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis. 1994;18:683-693.
92. McKinnon PS, Paladino JA, Grayson ML, Gibbons GW, Karchmer AW. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis. 1997;24:57-63.
93. Calandra GB, Raupp W, Brown KR. Imipenem/cilastatin treatment of lower extremity skin and soft tissue infections in diabetics. Scand J Infect Dis Suppl. 1987;52:15-19.
94. Ross CD, Pantig-Felix L, Kanat IO. Imipenem/cilastatin: its use in the treatment of foot infections in the compromised host. J Am Podiatr Med Assoc. 1988;78:361-367.
95. Lipman B, Neu HC. Imipenem: a new carbapenem antibiotic. Med Clin North Am. 1988;72:567-579.
96. Torres A, Ramirez-Ronda CH. Aztreonam in the treatment of soft tissue infections including diabetic foot infections. Bol Assoc Med P R. 1985;77:191-194.
97. Greenberg RN, Reilly PM, Luppen KL, et al. Treatment of serious gram-negative infections with aztreonam. J Infect Dis. 1984;150:623-630.
98. Graham DR, Lucasti C, Malafaia O, et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis. 2002; 34:1460-1468.
99. Gesser RM, McCarroll KA, Woods GL. Efficacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections: results of a double-blind clinical trial versus piperacillin-tazobactam. Int J Antimicrob Agents. 2004;23:235-239.
100. Boyce JM, Havill NL, Kohan C, Dumigan DG, Ligi CE. Do infection control measures work for methicillin-resistant Staphylococcus aureus? Infect Control Hosp Epidemiol. 2004;25:395-401.
101. Herwaldt LA. Control of methicillin-resistant Staphylococcus aureus in the hospital setting. Am J Med. 1999;106:S11-S18.
102. Karchmer TB, Durbin LJ, Simonton BM, Farr BM. Cost-effectiveness of active surveillance cultures and contact/droplet precautions for control of methicillin-resistant Staphylococcus aureus. J Hosp Infect. 2002;51:126-132.
103. Bernard L, Vaudaux P, Vuagnat A, et al, and the Osteomyelitis Study Group. Effect of vancomycin therapy for osteomyelitis on colonization by methicillin-resistant Staphylococcus aureus: lack of emergence of glycopeptide resistance. Infect Control Hosp Epidemiol. 2003;24:650-654.
104. Turco TF, Melko GP, Williams JR. Vancomycin intermediate-resistant Staphylococcus aureus. Ann Pharmacother. 1998;32:758-760.
105. Linares J. The VISA/GISA problem: therapeutic implications. Clin Microbiol Infect. 2001;7:S8-S15.
106. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis. 2001;32:402-412.
107. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002; 34:1481-1490.
108. Rayner CR, Baddour LM, Birmingham MC, Norden C, Meagher AK, Schentag JJ. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection. 2004;32:8-14.
109. Lipsky BA, Itani K, Norden C. Linezolid Diabetic Foot Infections Study Group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin- clavulanate. Clin Infect Dis. 2004;38:17-24.
110. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis. 2003;36:473-481.
111. Raad I, Hachem R, Hanna H, et al. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother. 2004;53:646-649.
112. Levison ME, Mallela S. Increasing antimicrobial resistance: therapeutic implications for enterococcal infections. Curr Infect Dis Rep. 2000;2:417-423.
113. LaPlante KL, Rybak MJ. Daptomycin-a novel antibiotic against Gram-positive pathogens. Expert Opin Pharmacother. 2004;5:2321-2331.
114. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis. 2004;38:994-1000.
115. Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs. 2004;64:1621-1642.
116. Abbanat D, Macielag M, Bush K. Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert Opin Investig Drugs. 2003;12:379-399.
117. Farber DC, Juliano PJ, Cavanagh PR, Ulbrecht J, Caputo G. Single stage correction with external fixation of the ulcerated foot in individuals with Charcot neuroarthropathy. Foot Ankle Int. 2002; 23:130-134.
118. Jolly GP, Zgonis T, Polyzois V. External fixation in the management of Charcot neuroarthropathy. Clin Podiatr Med Surg. 2003;20:741-756.
119. Cooper PS. Application of external fixators for management of Charcot deformities of the foot and ankle. Foot Ankle Clin. 2002;7:207-254.
120. Wang JC, Le AW, Tsukuda RK. A new technique for Charcot's foot reconstruction. J Am Podiatr Med Assoc. 2002;92:429-436.
121. Cooper PS. Application of external fixators for management of Charcot deformities of the foot and ankle. Semin Vasc Surg. 2003;16:67-78.
122. Wang JC. Use of external fixation in the reconstruction of the Charcot foot and ankle. Clin Podiatr Med Surg. 2003;20:97-117.
123. Prokuski LJ, Saltzman CL. External fixation for the treatment of Charcot arthropathy of the ankle: a case report. Foot Ankle Int. 1998;19:336-341.
124. Wang J, Li F, Calhoun JH, Mader JT. The role and effectiveness of adjunctive hyperbaric oxygen therapy in the management of musculoskeletal disorders. Postgrad Med. 2002;48:226-231.
125. Unger HD, Lucca M. The role of hyperbaric oxygen therapy in the treatment of diabetic foot ulcers and refractory osteomyelitis. Clin Podiatr Med Surg. 1990;7:483-493.
126. Clark LA, Moon RE. Hyperbaric oxygen in the treatment of life-threatening soft-tissue infections. Respir Care Clin North Am. 1999;5:203-219.
127. Esterhai JL, Pisarello J, Brighton CT, Heppenstall RB, Gellman H, Goldstein G. Adjunctive hyperbaric oxygen therapy in the treatment of chronic refractory osteomyelitis. J Trauma. 1987;27:763-768.
128. Cohn GH. Hyperbaric oxygen therapy. Promoting healing in difficult cases. Postgrad Med. 1986; 79:89-92.
129. Bakker, DJ. Hyperbaric oxygen therapy and the diabetic foot. Diabetes Metab Res Rev. 2000; 16:S55-S58.
130. Calhoun JH, Cobos JA, Mader JT. Does hyperbaric oxygen have a place in the treatment of osteomyelitis? Orthop Clin North Am. 1991;22:467-471.
131. Kessler L, Bilbault P, Ortega F, et al. Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diabetes Care. 2003;26:2378-2382.
132. Kalani M, Jorneskog G, Naderi N, Lind F, Brismar K. Hyperbaric oxygen (HBO) therapy in the treatment of diabetic foot ulcers. Long-term follow-up. J Diabetes Complications. 2002; 16:153-158.
133. Yonem A, Cakir B, Guler S, Azal O, Corakci A. Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes Metab. 2001;3:332-337.
134. Kastenbauer T, Hornlein B, Sokol G, Irsigler K. Evaluation of granulocyte-colony stimulating factor (Filgrastim) in infected diabetic foot ulcers. Diabetologia. 2003;46:27-30.
135. Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J, Edmonds ME. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet. 1997;350:855-859.
136. Peck KR, Son DW, Song JH, Kim S, Oh MD, Choe KW. Enhanced neutrophil functions by recombinant human granulocyte colony-stimulating factor in diabetic patients with foot infections in vitro. J Korean Med Sci. 2001;16:39-44.
137. Buchholz H, Engelbrecht H. Über die depotwirkung eineger antibiotica bei vermischung mit dem kunstharz palaces. Chiururg. 1970;41:511-515.
138. Markinko DE. Gentamycin-impregnated PMMA beads: an introduction and review. J Foot Surg. 1985;24:116-121.
139. Stabile DE, Jacobs AM. Local antibiotic treatment of soft tissue and bone infections of the foot. J Amer Podiatr Med Assoc. 1990;80:345-353.
140. Jacobs AM, Siefert AM, Kirisits TJ, Protzel HR. Use of antibiotic-loaded bone cement in the management of common infections of the foot and ankle. Clin Podiatr Med Surg. 1990;7:523-544.
141. Roeder B, Van Gils CC, Mailing S. Antibiotic beads in the treatment of diabetic pedal osteomyelitis. J Foot Ankle Surg. 2000;39:124-130.